A comprehensive overview of exosomes as drug delivery vehicles - Endogenous nanocarriers for targeted cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 75-87

  Johnsen, Kasper Bendix ^a   Gudbergsson, Johann Mar ^a   Skov, Martin Najbjerg ^a   Pilgaard, Linda ^a   Moos, Torben ^a   Duroux, Meg ^a  

^a AALBORG UNIVERSITY   (Denmark)

Author keywords

Cancer; Chemotherapy; Drug delivery; Exosome; Loading; Targeted therapy

Indexed keywords

3,3' (1,4 PHENYLENE)BIS[N [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ACRYLAMIDE]; CURCUMIN; DOXORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; MICRORNA; SMALL INTERFERING RNA; TEMOZOLOMIDE; TETRASPANIN; CUCURBITACIN; CYCLOPHOSPHAMIDE; FLUCYTOSINE; JSI 124; LET 7A; MELANOMA ANTIGEN 3; MICRORNA 143; MIR 146B; MIR 150; NANOCARRIER; NANOPARTICLE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIOGENESIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COLON ADENOCARCINOMA; COLORECTAL CANCER; DEGRADATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; EXOSOME; FIBROSARCOMA; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; MESENCHYMAL STEM CELL; MULTIVESICULAR BODY; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; RNA DEGRADATION; SIGNAL TRANSDUCTION; STOMACH CANCER; SURFACE PROPERTY; SYSTEMATIC REVIEW; VIRUS REPLICATION; AUTOLOGOUS ASCITES DERIVED EXOSOME; CANCER GENE THERAPY; CELL ACTIVATION; DENDRITIC CELL DERIVED EXOSOME; ENCAPSULATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEURILEMOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING;

CANCER; CHEMOTHERAPY; DRUG DELIVERY; EXOSOME; LOADING; TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; EXOSOMES; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; PHARMACEUTICAL VEHICLES;

EID: 84899825335     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.04.005     Document Type: Review

References (122)

1. Record M., Subra C., Silvente-Poirot S., Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 2011, 81:1171-1182.
2. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 2012, 1820:940-948.
3. Witwer K.W., Buzás E.I., Bemis L.T., Bora A., Lässer C., Lötvall J., et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2013, 2:18389.
4. Jia S., Zocco D., Samuels M.L., Chou M.F., Chammas R., Skog J., et al. Emerging technologies in extracellular vesicle-based molecular diagnostics. Expert. Rev. Mol. Diagn. 2014, (E-pub ahead of print).
5. Trams E.G., Lauter C.J., Salem N., Heine U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim. Biophys. Acta 1981, 645:63-70.
6. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33:967-978.
7. Johnstone R.M., Adam M., Hammond J.R., Orr L., Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 1987, 262:9412-9420.
8. Johnstone R.M., Mathew A., Mason A.B., Teng K. Exosome formation during maturation of mammalian and avian reticulocytes: evidence that exosome release is a major route for externalization of obsolete membrane proteins. J. Cell. Physiol. 1991, 147:27-36.
9. El Andaloussi S., Mäger I., Breakefield X.O., Wood M.J.A. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12:347-357.
10. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183:1161-1172.
11. Riteau B., Faure F., Menier C., Viel S., Carosella E.D., Amigorena S., et al. Exosomes bearing HLA-G are released by melanoma cells. Hum. Immunol. 2003, 64:1064-1072.
12. Caby M.-P., Lankar D., Vincendeau-Scherrer C., Raposo G., Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 2005, 17:879-887.
13. Raiborg C., Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 2009, 458:445-452.
14. Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G., Geeraerts A., et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 2012, 14:677-685.
15. Trajkovic K., Hsu C., Chiantia S., Rajendran L., Wenzel D., Wieland F., et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319:1244-1247.
16. Ostrowski M., Carmo N.B., Krumeich S., Fanget I., Raposo G., Savina A., et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 2010, 12:1-13. (sup).
17. Bobrie A., Colombo M., Raposo G., Thery C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011, 12:1659-1668.
18. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
19. Yeo R.W.Y., Lai R.C., Zhang B., Tan S.S., Yin Y., Teh B.J., et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 2013, 65:336-341.
20. Chen T.S., Arslan F., Yin Y., Tan S.S., Lai R.C., Choo A.B.H., et al. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J. Transl. Med. 2011, 9:47.
21. Koumangoye R.B., Sakwe A.M., Goodwin J.S., Patel T., Ochieng J. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS ONE 2011, 6:e24234.
22. Conde-Vancells J., Rodriguez-Suarez E., Embade N., Gil D., Matthiesen R., Valle M., et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J. Proteome Res. 2008, 7:5157-5166.
23. Lässer C., Eldh M., Lötvall J. Isolation and characterization of RNA-containing exosomes. J. Vis. Exp. 2012, e3037.
24. Lee Y., El Andaloussi S., Wood M.J.A. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 2012, 21:125-134.
25. Mathivanan S., Fahner C.J., Reid G.E., Simpson R.J. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012, 40:D1241-D1244.
26. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
27. Skog J., Würdinger T., Van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
28. Katakowski M., Buller B., Wang X., Rogers T., Chopp M. Functional microRNA is transferred between glioma cells. Cancer Res. 2010, 70:8259-8263.
29. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20:847-856.
30. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Urbanowicz B., Brański P., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol. Immunother. 2006, 55:808-818.
31. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol. Lett. 2007, 113:76-82.
32. Gatti S., Bruno S., Deregibus M.C., Sordi A., Cantaluppi V., Tetta C., et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 2011, 26:1474-1483.
33. Lai R.C., Arslan F., Lee M.M., Sze N.S.K., Choo A., Chen T.S., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010, 4:214-222.
34. Del Conde I., Shrimpton C.N., Thiagarajan P., López J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005, 106:1604-1611.
35. Lachenal G., Pernet-Gallay K., Chivet M., Hemming F.J., Belly A., Bodon G., et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol. Cell. Neurosci. 2011, 46:409-418.
36. Lai C.P.-K., Breakefield X.O. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front. Physiol. 2012, 3:228.
37. Théry C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
38. Katsuda T., Kosaka N., Ochiya T. The roles of extracellular vesicles in cancer biology: towards the development of novel cancer biomarkers. Proteomics 2013, 14:412-425.
39. Mailloux A.W., Epling-Burnette P.K. Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. OncoImmunology 2013, 2:e22654.
40. Kim J.W., Wieckowski E., Taylor D.D., Reichert T.E., Watkins S., Whiteside T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005, 11:1010-1020.
41. Wieckowski E.U., Visus C., Szajnik M., Szczepanski M.J., Storkus W.J., Whiteside T.L. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J. Immunol. 2009, 183:3720-3730.
42. Hoshino D., Kirkbride K.C., Costello K., Clark E.S., Sinha S., Grega-Larson N., et al. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep. 2013, 5:1159-1168.
43. Hoshino D., Branch K.M., Weaver A.M. Signaling inputs to invadopodia and podosomes. J. Cell Sci. 2013, 126:2979-2989.
44. Christianson H.C., Svensson K.J., van Kuppevelt T.H., Li J.-P., Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17380-17385.
45. Rak J., Guha A. Extracellular vesicles-vehicles that spread cancer genes. Bioessays 2012, 34:489-497.
46. Sidhu S.S., Mengistab A.T., Tauscher A.N., LaVail J., Basbaum C. The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 2004, 23:956-963.
47. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
48. Kucharzewska P., Christianson H.C., Welch J.E., Svensson K.J., Fredlund E., Ringnér M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7312-7317.
49. Tadokoro H., Umezu T., Ohyashiki K., Hirano T., Ohyashiki J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288:34343-34351.
50. Ramteke A., Ting H., Agarwal C., Mateen S., Somasagara R., Hussain A., et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol. Carcinog. 2013, (E-pub ahead of print).
51. Sharma S., Das K., Woo J., Gimzewski J.K. Nanofilaments on glioblastoma exosomes revealed by peak force microscopy. J. R. Soc. Interface 2014, 11:20131150.
52. Mizoguchi M., Guan Y., Yoshimoto K., Hata N., Amano T., Nakamizo A., et al. Clinical implications of microRNAs in human glioblastoma. Front. Oncol. 2013, 3:19.
53. Noerholm M., Balaj L., Limperg T., Salehi A., Zhu L.D., Hochberg F.H., et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 2012, 12:22.
54. Gonda D.D., Akers J.C., Kim R., Kalkanis S.N., Hochberg F.H., Chen C.C., et al. Neuro-oncologic applications of exosomes, microvesicles, and other nano-sized extracellular particles. Neurosurgery 2013, 72:501-510.
55. Lässer C. Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Expert. Opin. Biol. Ther. 2012, 12(Suppl. 1):S189-S197.
56. Duijvesz D., Burnum-Johnson K.E., Gritsenko M.A., Hoogland A.M., Vredenbregt-van den Berg M.S., Willemsen R., et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS ONE 2013, 8:e82589.
57. Yamashita T., Kamada H., Kanasaki S., Maeda Y., Nagano K., Abe Y., et al. Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. Pharmazie 2013, 68:969-973.
58. Maguire C.A., Balaj L., Sivaraman S., Crommentuijn M.H.W., Ericsson M., Mincheva-Nilsson L., et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol. Ther. 2012, 20:960-971.
59. Pan Q., Ramakrishnaiah V., Henry S., Fouraschen S., de Ruiter P.E., Kwekkeboom J., et al. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2012, 61:1330-1339.
60. Kosaka N., Iguchi H., Yoshioka Y., Hagiwara K., Takeshita F., Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J. Biol. Chem. 2012, 287:1397-1405.
61. Ohno S.-I., Takanashi M., Sudo K., Ueda S., Ishikawa A., Matsuyama N., et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 2012, 21:185-191.
62. Wahlgren J., Karlson T.D.L., Brisslert M., Vaziri Sani F., Telemo E., Sunnerhagen P., et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012, 40:130.
63. Mizrak A., Bolukbasi M.F., Ozdener G.B., Brenner G.J., Madlener S., Erkan E.P., et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol. Ther. 2013, 21:101-108.
64. Shtam T.A., Kovalev R.A., Varfolomeeva E.Y., Makarov E.M., Kil Y.V., Filatov M.V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun. Signal. 2013, 11:88.
65. Hood J.L., Scott M.J., Wickline S.A. Maximizing exosome colloidal stability following electroporation. Anal. Biochem. 2013, 448C:41-49.
66. Takahashi Y., Nishikawa M., Shinotsuka H., Matsui Y., Ohara S., Imai T., et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J. Biotechnol. 2013, 165:77-84.
67. Lee Y.S., Kim S.H., Cho J.A., Kim C.W. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp. Mol. Med. 2011, 43:281-290.
68. Yin W., Ouyang S., Li Y., Xiao B., Yang H. Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity. Inflammation 2013, 36:232-240.
69. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J.A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
70. Tian Y., Li S., Song J., Ji T., Zhu M., Anderson G.J., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2013, (E-pub ahead of print).
71. Xin H., Li Y., Buller B., Katakowski M., Zhang Y., Wang X., et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 2012, 30:1556-1564.
72. Munoz J.L., Bliss S.A., Greco S.J., Ramkissoon S.H., Ligon K.L., Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids 2013, 2:e126.
73. Katakowski M., Buller B., Zheng X., Lu Y., Rogers T., Osobamiro O., et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013, 335:201-204.
74. Zhu W., Huang L., Li Y., Zhang X., Gu J., Yan Y., et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012, 315:28-37.
75. Bruno S., Collino F., Deregibus M.C., Grange C., Tetta C., Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2013, 22:758-771.
76. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61:746-759.
77. Lin Q., Chen J., Zhang Z., Zheng G. Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine (Lond.) 2014, 9:105-120.
78. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Deliv. Rev. 2013, 66:110-116.
79. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3:406-417.
80. Zhang Y., Liu D., Chen X., Li J., Li L., Bian Z., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 2010, 39:133-144.
81. Bryniarski K., Ptak W., Jayakumar A., Püllmann K., Caplan M.J., Chairoungdua A., et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J. Allergy Clin. Immunol. 2013, 132:170-181.
82. Chen L., Charrier A., Zhou Y., Chen R., Yu B., Agarwal K., et al. Epigenetic regulation of connective tissue growth factor by microRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2013, 59:1118-1129.
83. Gressner O.A., Gressner A.M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008, 28:1065-1079.
84. Møller H.G., Rasmussen A.P., Andersen H.H., Johnsen K.B., Henriksen M., Duroux M. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol. Neurobiol. 2013, 47:131-144.
85. Henriksen M., Johnsen K.B., Andersen H.H., Pilgaard L., Duroux M. MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme-a systematic overview. Mol. Neurobiol. 2014, (E-pub ahead of print).
86. Katakowski M., Zheng X., Jiang F., Rogers T., Szalad A., Chopp M. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Investig. 2010, 28:1024-1030.
87. Villarroya-Beltri C., Gutiérrez-Vázquez C., Sánchez-Cabo F., Pérez-Hernández D., Vázquez J., Martin-Cofreces N., et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 2013, 4:2980.
88. Jang S.C., Kim O.Y., Yoon C.M., Choi D.-S., Roh T.-Y., Park J., et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 2013, 7:7678-7710.
89. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65:157-170.
90. Zhuang X., Xiang X., Grizzle W., Sun D., Zhang S., Axtell R.C., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19:1769-1779.
91. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63:1270-1279.
92. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18:1606-1614.
93. Hamstra D.A., Lee K.C., Tychewicz J.M., Schepkin V.D., Moffat B.A., Chen M., et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol. Ther. 2004, 10:916-928.
94. Rachakatla R.S., Balivada S., Seo G.-M., Myers C.B., Wang H., Samarakoon T.N., et al. Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 2010, 4:7093-7104.
95. Kooijmans S.A.A., Stremersch S., Braeckmans K., de Smedt S., Hendrix A., Wood M.J.A., et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control. Release 2013, 172:229-238.
96. Neumann E., Schaefer-Ridder M., Wang Y., Hofschneider P.H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1982, 1:841-845.
97. El Andaloussi S., Lee Y., Lakhal-Littleton S., Li J., Seow Y., Gardiner C., et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 2012, 7:2112-2126.
98. Rana S., Yue S., Stadel D., Zöller M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem. Cell Biol. 2012, 44:1574-1584.
99. Jaruga E., Sokal A., Chrul S., Bartosz G. Apoptosis-independent alterations in membrane dynamics induced by curcumin. Exp. Cell Res. 1998, 245:303-312.
100. Barry J., Fritz M., Brender J.R., Smith P.E.S., Lee D.-K., Ramamoorthy A. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J. Am. Chem. Soc. 2009, 131:4490-4498.
101. Jo W., Jeong D., Kim J., Cho S., Jang S.C., Han C., et al. Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers. Lab Chip 2014, (E-pub ahead of print).
102. Nedergaard M.K., Hedegaard C.J., Poulsen H.S. Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs 2012, 26:83-99.
103. Grapp M., Wrede A., Schweizer M., Hüwel S., Galla H.-J., Snaidero N., et al. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat. Commun. 2013, 4:2123.
104. Chen Y., Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 2012, 64:640-665.
105. Sokolova V., Ludwig A.-K., Hornung S., Rotan O., Horn P.A., Epple M., et al. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf. B: Biointerfaces 2011, 87:146-150.
106. Kalra H., Adda C.G., Liem M., Ang C.-S., Mechler A., Simpson R.J., et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 2013, 13:3354-3364.
107. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
108. Kaasgaard T., Andresen T.L. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin. Drug Deliv. 2010, 7:225-243.
109. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 1992, 267:18759-18765.
110. Takino T., Nakajima C., Takakura Y., Sezaki H., Hashida M. Controlled biodistribution of highly lipophilic drugs with various parenteral formulations. J. Drug Target. 1993, 1:117-124.
111. Natarajan A., Wagner B., Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17081-17086.
112. Mortensen J.H., Jeppesen M., Pilgaard L., Agger R., Duroux M., Zachar V., et al. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J. Drug Deliv. 2013, 2013:209205.
113. Hong B., Wiese B., Bremer M., Heissler H.E., Heidenreich F., Krauss J.K., et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme. Am. J. Clin. Oncol. 2013, 36:261-268.
114. Ju S., Mu J., Dokland T., Zhuang X., Wang Q., Jiang H., et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol. Ther. 2013, 21:1345-1357.
115. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
116. Escrevente C., Keller S., Altevogt P., Costa J. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer 2011, 11:108.
117. El Andaloussi S., Lakhal S., Mäger I., Wood M.J.A. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 2012, 65:391-397.
118. Subra C., Laulagnier K., Perret B., Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 2007, 89:205-212.
119. Kooijmans S.A.A., Vader P., van Dommelen S.M., van Solinge W.W., Schiffelers R.M. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomedicine 2012, 7:1525-1541.
120. Escudier B., Dorval T., Chaput N., André F., Caby M.-P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl. Med. 2005, 3:10.
121. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 2005, 3:9.
122. Dai S., Wei D., Wu Z., Zhou X., Wei X., Huang H., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 2008, 16:782-790.